Search Results - "Magnes, T."

The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab by Magnes, T, Melchardt, T, Hufnagl, C, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Rinnerthaler, G, Roesch, S, Gaggl, A, Greil, R, Egle, A

“…FCGR2A-H131R and FCGR3A-V157F are single-nucleotide polymorphisms known to influence the outcome of patients treated with rituximab, cetuximab and trastuzumab…”
Get full text

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab by Magnes, T., Melchardt, T., Hufnagl, C., Weiss, L., Mittermair, C., Neureiter, D., Klieser, E., Rinnerthaler, G., Roesch, S., Gaggl, A., Greil, R., Egle, A.

“…In the abstract and in other parts of the manuscript the authors wrote that the mutation rs396991 causes a valine (V) to phenylalanine (F) substitution at…”
Get full text

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence by Magnes, T., Wagner, S., Thorner, A.R., Neureiter, D., Klieser, E., Rinnerthaler, G., Weiss, L., Huemer, F., Zaborsky, N., Steiner, M., Weis, S., Greil, R., Egle, A., Melchardt, T.

“…The prognosis of patients with secondary central nervous system lymphoma (SCNSL) is poor and despite massive advances in understanding the mutational landscape…”
Get full text

An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer by Winder, T., Posch, F., Asamer, E., Stotz, M., Siebenhüner, A., Schlick, K., Magnes, T., Samaras, P., Szkandera, J., Clavien, P.-A., Neureiter, D., Greil, R., Pestalozzi, B.C., Stoeger, H., Gerger, A., Egle, A., Pichler, M.

Get full text